News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nycomed Canada Solidifies Leadership Position in the Canadian Respiratory Market


6/26/2008 2:58:53 PM

OAKVILLE, ON, June 26 /CNW/ - Nycomed Canada Inc. today announced a licensing agreement with Chiesi Farmaceutici SpA to market Atimos(R) (formoterol), a treatment anticipated to be indicated for asthma and Chronic Obstructive Pulmonary Disease (COPD). In Canada, COPD is the fourth-leading cause of death among Canadians, and recently The Lung Association reported that COPD may affect nearly three million diagnosed and undiagnosed Canadians.

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES